Experience

Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $380 million acquisition of HemaCare Corporation. The proposed purchase price equates to $25.40…

Davis Polk is advising Roche on its acquisition of Promedior, Inc. Under the terms of the merger agreement, Roche will make an upfront cash payment of $390 million, plus additional…

Davis Polk advised Centogene N.V. on its $56 million initial public offering of 4,000,000 of its common shares. In addition, Centogene has granted the underwriters a 30-day option to…

Davis Polk advised the underwriters in connection with a $38.4 million initial public offering of common stock of RAPT Therapeutics, Inc. RAPT Therapeutics’ common stock is listed on…

Davis Polk advised the underwriters on the SEC-registered initial public offering by Progyny, Inc. of 11,500,000 common shares, consisting of 6,700,000 shares sold by Progyny and 4,800,000…

Davis Polk advised the underwriters in connection with an initial public offering of 8,047,227 American Depositary Shares of Innate Pharma S.A. and a concurrent private placement of 4,452…

Davis Polk advised the underwriters in connection with the $150 million initial public offering of 10,000,000 American Depositary Shares of BioNTech SE. In addition, the underwriters have…

Davis Polk advised the underwriters in connection with the $97.75 million initial public offering of 6,516,667 shares of common stock of Aprea Therapeutics, Inc., which includes 850,000…

Davis Polk advised TPG Capital, the private equity platform of global alternative asset firm TPG, on its acquisition of Convey Health Solutions from New Mountain Capital and related…

Davis Polk is advising the Goldman Sachs Merchant Banking Division in connection with its investment in MedVet. Founded in 1869, The Goldman Sachs Group, Inc. is a leading global investment…